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Lab Medicine Winter 2015 | Volume 46, Number 1 www.labmedicine.com Case Studies 2. Thrombocytosis in an adult can be primary or secondary in nature. Primary thrombocytosis is characteristic of all of the myeloproliferative disorders, myelodysplasia, and other myeloid malignant neoplasms. In these hematopathologic manifestations, there is uncontrolled production of the megakaryocytes in the bone marrow that results in a marked increase in the number of circulating platelets. The peripheral blood platelet count often exceeds 1000 x 10 3 per μL.
Secondary thrombocytosis is also known as reactive thrombocytosis. In this circumstance, an underlying condition is responsible for the increased platelet count. Common causes of reactive thrombocytosis include acute hemorrhage, malignant disease, chronic inflammatory disease, iron deficiency anemia, and hemolytic anemia. The circulating platelet count in secondary thrombocytosis may approach 1000 x 10 3 per μL; however, platelet numbers observed in reactive thrombocytosis generally are not as numerous as in primary thrombocytosis. Treating the underlying condition is the key to reestablishing a normal platelet count.
Microcytosis has many causes, the most prevalent being iron-deficiency anemia. Other microcytic hematopathologic manifestations include anemia of chronic disease, sideroblastic anemia, spherocytosis, and thalassemias.
3. The peripheral blood specimen from the patient contains a markedly increased platelets and erythrocytes of markedly decreased volume, although they are well filled with hemoglobin ( Figure 1 , Table 1 ). Diagnosis should focus on determining whether the thrombocytosis of the patient is primary or secondary, as well as on establishing the etiology that underlies her microcytosis. JAK2V617F mutation screening is part of the diagnostic workup for thrombocytosis, according to the World Health Organization. 1 The JAK2 gene (147796) encodes a member of a family of 4 Janus kinases (JAKs): 1, 2, 3 (JAK1, JAK2, JAK3), and tyrosine kinase 2 (Tyk2). These kinases associate with cytokine receptors; on activation of the receptors, the JAKs phosphorylate signal transducer and activator of transcription (STAT) transcription factors and thus initiate the JAK-STAT signaling pathway. JAKs have 7 defined regions of homology called Janus homology (JH) domains 1 through 7 (JH1-7). JH1 is the kinase domain that imparts enzymatic activity to the JAK. JH2 is a pseudokinase domain that is essential for normal kinase activity yet lacks enzymatic activity itself. The remaining domains, namely, The V617F mutation is a change from valine to phenylalanine at the 617 position in the JH2 domain. In hematopoietic cells, this results in the cell becoming more sensitive to such hematopoietic growth factors as erythropoietin and thrombopoietin. Thus, the V617F mutation is a gain of function mutation that gives the cell a proliferation advantage. Mutations in JAK2 are often implicated in all of the myeloproliferative disorders of primary thrombocytosis. 2 Because the mutation screening for the patient does not reveal a JAK2 abnormality, myeloproliferative leukemia virus (MPL) oncogene and calreticulin (CALR) mutation testing might be informative. It has been shown 3,4 that patients with myeloproliferative neoplasms who test JAK2 negative may harbor mutations in these genes.
The platelet count of our patient, which exceeded 1000 x 10 3 per μL, is suggestive of primary thrombocytosis; however, her normal total white blood cell (WBC) count and her essentially normal differential count are not suggestive of the myelocytic irregularities expected with primary thrombocytosis. The patient's JAK2 V617F mutation test was negative, which by itself, does not rule out primary thrombocytosis but it increases the likelihood that the high platelet count of the patient is reactive, or secondary, in nature. However, her essentially normal WBC results also do not suggest inflam- Despite an initial complete blood count (CBC) that was somewhat incongruous with iron deficiency anemia, we assessed the iron status of the patient. Her normal iron panel excludes iron deficiency anemia as an underlying cause of her thrombocytosis ( Table 2) . Of note, although we used the iron panel to rule out iron deficiency anemia in this patient, it also would be reasonable to investigate her serum transferrin receptor (sTfR) and zinc protoporphyrin levels, especially because her serum iron level is close to the lower limits of the normal range.
The CBC results from our patient were not reflective of an inflammatory process, and her normal erythrocyte sedimentation rate (ESR) and low C-reactive protein level ( Table 2 ) supported the conclusion that her high platelet count is not a reactive thrombocytosis developing from an inflammatory or malignant condition. Sideroblastic anemia could be considered; however, the normal ferritin level and Case Studies the absence of dual populations of normochromic and hypochromic erythrocytes in our patient make this conclusion unlikely. Several hematopathologic manifestations involve spherocytes in the peripheral blood; however, the presence of spherocytes in these pathologic entities is not prevalent enough to markedly decrease the mean cell volume (MCV), other than in hereditary spherocytosis.
In the case of our patient, her normal mean cell hemoglobin concentration (MCHC) describes cells that are normally filled rather than overfilled with hemoglobin, which makes a diagnosis of spherocytosis improbable. Ruling out the other causes of microcytosis leaves the thalassemias as a possible explanation for the microcytosis observed in the patient. Hemoglobin electrophoresis testing revealed a completely normal electrophoretic pattern that disfavors the β-thalassemias other than the silent carrier type. A normal electrophoretic pattern also makes α-thalassemia major improbable; however, α-thalassemia trait could display normal hemoglobin electrophoresis.
To confirm a diagnosis of α-thalassemia trait and to elucidate the exact genetic nature of the condition of the patient, we ordered molecular diagnostic testing. The panel of testing for α-thalassemia trait includes testing for 7 common deletions in the genes that determine α-thalassemia trait: -α3.7, -α4.2, -(α)20.5, --SEA , --
and --THAI . 6 The results determined that the patient possesses the --SEA genotype ( Table 2 ).
4. The normal human adult hemoglobin protein contains 2 α globin and 2 non-α globin polypeptides. The 2 globin polypeptides (α1 and α2) are encoded by 2 α genes on chromosome 16, HBA1, and a nearly identical gene located nearby, HBA2. These α-globin genes are part of an α-globin gene cluster. In addition to HBA1 and HBA2, the α-gene cluster includes a gene for embryonic globin (HBZ), 2 genes that code for minor proteins (HBD and HBQ), and 2 pseudo genes (HBA1ps and HBZps). These additional genes in the cluster code for ζ, αD, θ, ψα1, and ψζ proteins, respectively ( Figure 2) . Expression of the genes within the α-globin gene cluster is regulated by 4 highly conserved noncoding sequences, known as multispecies conserved sequences (MCS R1-4). They are located 25 kb to 65 kb upstream of the HBA genes.
Although MCS R1 through R4 are believed to be generegulatory sequences, only MCS R2 (major α-globin regulatory element) [HS-40]) appears to be essential for α-globulin expression. 7 Because humans have 2 copies of chromosome 16, a healthy adult encodes the 2 α-globin proteins of each of their hemoglobin molecules from 4 α genes (2 HBA1 and 2 HBA2 genes). Patients exhibiting α-thalassemia trait exhibit hemoglobin with reduced or absent α-globin chains, due to reduced expression of HBA1, HBA2, or both. A normal α-globin genotype is denoted as αα/αα, which indicates that all 4 α genes express normally; the genotype of patients with α-thalassemia can range from -α/αα (least severe) to --/--(most severe), indicating a loss of expression in at least 1 of the α genes. Phenotypically, patients exhibit the more severe variant, α-thalassemia major, if they possess the --/-α or the --/--genotype. --/-α results in hemoglobin H disease, and the --/--genotype results in hemoglobin Bart hydrops fetalis syndrome. The milder α-thalassemia trait is caused by the -α/αα, -α/-α (trans), or --/αα (cis) genotype. α-thalassemia trait caused by loss of gene expression in the cis configuration does not result in a more or a less severe phenotype than α-thalassemia trait that results from gene loss in the trans configuration; however, the arrangement that the patient possesses has considerable implications for genetic counseling of these individuals.
Reduced expression of the α gene(s) may be caused by deletional or nondeletional defects in the α gene itself or in regions near the gene that contribute to normal gene expression. Deletion of HBA1, HBA2, or of nearby crucial regions is the most frequent cause of α thalassemia. Dele- 
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Case Studies tions may partially or fully delete the α genes, their promoters, and/or regulatory regions. Much less frequently, α thalassemia is caused by nondeletional mutations. Nondeletional defects of the α-globin gene cluster are numerous and varied; these include point mutations, nucleotide insertions/deletions, in-frame deletions, frame-shift mutations, and nonsense mutations. The mutations affect cell processes such as transcription, translation, messenger RNA (mRNA) editing, and globin stability. 8, 9 5. This patient is indeed a candidate for genetic counseling, especially because she is a potential gamete donor. She has been diagnosed with --SEA ; both of her hemoglobin genes (HBA1 and HBA2) have been removed from 1 of her chromosome 16 copies. This α-thalassemia-trait genotype can have serious implications for her offspring. Case Studies other parent. The most serious outcome for the offspring of this individual is hemoglobin Bart hydrops fetalis syndrome, a fatal condition that results from the deletion of all 4 α-globin genes. If the father has α-thalassemia major in the form of Hemoglobin H disease, or if the father also has α-thalassemia trait with a gene deletion in a cis position, there is a 25% chance that the offspring of the mother can inherit this lethal form of α-thalassemia major ( Figure 3, parts a and b) . Even in the most-favorable circumstance, in which the father has a normal genotype, there is still a 50% chance that the offspring of the couple will inherit α-thalassemia trait with deletions of HBA1 and HBA2 in the cis configuration. In this case, the F2 generation will face the same risky inheritance issues that exist for the individual featured in this case study ( Figure 3 , part e).
The potentially lethal outcomes that exist for the offspring of this woman do not exist for individuals with α-thalassemia trait in the trans configuration. The most serious consequences exist for progeny of individuals with the trans configuration and patients with Hemoglobin H. Even in this worst-case scenario, the lethal combination that produces hemoglobin Bart hydrops fetalis syndrome is not possible (Figure 3 , part f).
Patient Treatment and Outcome
The patient was referred to a hematologist after routine bloodwork revealed anemia secondary to microcytosis and a markedly increased platelet count. Investigation of her microcytosis culminated in a diagnosis of α-thalassemia trait in the cis configuration, with an --SEA genotype.
The patient has continued to do well, with no health related concerns. Her anemia is very mild; no treatment for this condition is advocated at this time. We had planned to pursue testing regarding her thrombocythemia; however, given that her platelet count had dropped by a substantial 17% during a 10-day period, we decided to monitor her condition using CBCs every 4 to 6 weeks instead of pursuing more complex testing. This schedule of CBC testing will allow us to monitor her anemia simultaneously with any other conditions that may arise. If normalization of her platelet count does not occur, additional testing can be considered. The cause of the thrombocytopenia is likely reactive, perhaps exacerbated by the underlying thalassemia.
